BNB Plus Corp. completes production of $1.2M LineaDNA order

BNB Plus completed production of its largest order in LineaRx history. The $1.2M order, originally announced in January 2026 with shipments completing in early May 2026, was produced at historically higher margins with zero batch failures, demonstrating the technical excellence and manufacturing reliability of the LineaDNA platform for large-scale cell-free DNA production. Notably, the Company achieved a production cadence of more than 1.5 grams per week during fulfillment of this order, a new record for LineaRx and a further demonstration of the platform’s scalability and manufacturing maturity.